Treatment of ER-positive breast cancer cells with α-methyl-dl-tryptophan (α-MT), a selective blocker of SLC6A14, leads to amino acid deprivation, inhibition of the mTOR pathway, activation of autophagy, and induction of cancer cell apoptosis. Here, MTOR is linked to cancer.